Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse

Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse

BackgroundDespite treatment with high-dose chemotherapy followed by autologous stem cell transplantation (AHCT), patients with multiple myeloma (MM) invariably relapse. Molecular residual disease (MRD)-negativity post-AHCT has emerged as an important prognostic marker predicting the duration of remi...

Full description

Bibliographic Details
Main Authors: Binod Dhakal, Shruti Sharma, Mustafa Balcioglu, Svetlana Shchegrova, Meenakshi Malhotra, Bernhard Zimmermann, Paul R. Billings, Alexandra Harrington, Himanshu Sethi, Alexey Aleshin, Parameswaran N. Hari
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-02-01
Series:Frontiers in Oncology
Subjects:
circulating tumor DNA (ctDNA)
tumor-informed
minimal/molecular residual disease
multiple myeloma (MM)
multiparameter flow cytometry (MFC)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.786451/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.786451/full

Similar Items